[go: up one dir, main page]

MX2023011326A - Psilocybin compositions, methods of making and methods of using the same. - Google Patents

Psilocybin compositions, methods of making and methods of using the same.

Info

Publication number
MX2023011326A
MX2023011326A MX2023011326A MX2023011326A MX2023011326A MX 2023011326 A MX2023011326 A MX 2023011326A MX 2023011326 A MX2023011326 A MX 2023011326A MX 2023011326 A MX2023011326 A MX 2023011326A MX 2023011326 A MX2023011326 A MX 2023011326A
Authority
MX
Mexico
Prior art keywords
methods
compositions
psilocybin
making
same
Prior art date
Application number
MX2023011326A
Other languages
Spanish (es)
Inventor
David Philip Elder
Nigel Richardson
Original Assignee
Compass Pathfinder Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Pathfinder Ltd filed Critical Compass Pathfinder Ltd
Publication of MX2023011326A publication Critical patent/MX2023011326A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of psilocybin and one or more pharmaceutically acceptable excipients. Methods of making such compositions and use thereof in treating depressive disorders are also disclosed.
MX2023011326A 2021-03-30 2022-03-30 Psilocybin compositions, methods of making and methods of using the same. MX2023011326A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163168055P 2021-03-30 2021-03-30
PCT/EP2022/058483 WO2022207746A1 (en) 2021-03-30 2022-03-30 Psilocybin compositions, methods of making and methods of using the same

Publications (1)

Publication Number Publication Date
MX2023011326A true MX2023011326A (en) 2023-10-03

Family

ID=81448508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011326A MX2023011326A (en) 2021-03-30 2022-03-30 Psilocybin compositions, methods of making and methods of using the same.

Country Status (15)

Country Link
US (1) US20240197758A1 (en)
EP (1) EP4312995A1 (en)
JP (1) JP2024512983A (en)
KR (1) KR20230175186A (en)
CN (1) CN117460498A (en)
AR (2) AR125250A1 (en)
AU (1) AU2022246987A1 (en)
BR (1) BR112023018472A2 (en)
CA (1) CA3210649A1 (en)
CO (1) CO2023013050A2 (en)
IL (1) IL305435A (en)
MX (1) MX2023011326A (en)
PH (1) PH12023552741A1 (en)
TW (1) TW202304466A (en)
WO (1) WO2022207746A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
WO2022153266A1 (en) 2021-01-15 2022-07-21 Beckley Psytech Limited Ergoline analogues
US20250000881A1 (en) * 2021-11-09 2025-01-02 Compass Pathfinder Limited Treatment of treatment resistant depression with psilocybin
JP2025500844A (en) 2021-12-13 2025-01-15 コンパス パスファインダー リミテッド Psilocybin and adjunctive serotonin reuptake inhibitors for use in the treatment of treatment-resistant depression - Patents.com
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006227684B2 (en) 2005-03-23 2012-01-12 Bpsi Holdings, Llc. Agglomerated starch compositions
US20210069170A1 (en) * 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
GB2571696B (en) * 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20220096504A1 (en) * 2019-01-30 2022-03-31 Diamond Therapeutics Inc. Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavorial, and/or mood disorders
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US11766445B2 (en) * 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound
US20250000881A1 (en) * 2021-11-09 2025-01-02 Compass Pathfinder Limited Treatment of treatment resistant depression with psilocybin
JP2025500844A (en) * 2021-12-13 2025-01-15 コンパス パスファインダー リミテッド Psilocybin and adjunctive serotonin reuptake inhibitors for use in the treatment of treatment-resistant depression - Patents.com

Also Published As

Publication number Publication date
PH12023552741A1 (en) 2024-03-04
EP4312995A1 (en) 2024-02-07
US20240197758A1 (en) 2024-06-20
AR126005A1 (en) 2023-08-30
BR112023018472A2 (en) 2023-10-10
TW202304466A (en) 2023-02-01
KR20230175186A (en) 2023-12-29
AU2022246987A1 (en) 2023-09-07
AR125250A1 (en) 2023-06-28
CN117460498A (en) 2024-01-26
IL305435A (en) 2023-10-01
CO2023013050A2 (en) 2023-10-19
WO2022207746A1 (en) 2022-10-06
CA3210649A1 (en) 2022-10-06
JP2024512983A (en) 2024-03-21

Similar Documents

Publication Publication Date Title
PH12023552741A1 (en) Psilocybin Compositions, Methods Of Making And Methods Of Using The Same
PH12022551379A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
MX2021005924A (en) Compounds and methods of use thereof for treatment of cancer.
MX2021004639A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors.
MX2023001997A (en) Bicyclic compounds, compositions and use thereof.
MX2023010411A (en) Erbb/btk inhibitors.
MX2023009682A (en) Tyk2 inhibitors and uses thereof.
MX2023003677A (en) Hsd17b13 inhibitors and uses thereof.
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
CR20240144A (en) Azetidine and pyrrolidine parp1 inhibitors and uses thereof
MX2023009685A (en) Tyk2 inhibitors and uses thereof.
JOP20190191A1 (en) Therapeutic dendrimers
MX2023010711A (en) Phenalkylamines and methods of making and using the same.
ZA202306956B (en) Long acting injectable compositions of cariprazine or its pharmaceutically acceptable salts
TN2022000185A1 (en) Methods of treating splenomegaly
MX2023009723A (en) Tyk2 inhibitors and uses thereof.
MX2023003675A (en) Hsd17b13 inhibitors and uses thereof.
MX2024013020A (en) Heteroaryl compounds for the treatment of pain
MX2024014262A (en) Inhibitors of parg
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
MX2019015280A (en) Statin compositions and methods for use in treating synucleinopathies.
MX2022012001A (en) Preventative treatment of migraine.
CR20240514A (en) Heteroaryl compounds for the treatment of pain
MX2021011289A (en) Compositions comprising pkm2 modulators and methods of treatment using the same.
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban